Recall due to reduced active ingredient content

Effectiveness cannot be guaranteed.

According to § 14 of the Federal Disability Equality Act (BGStG) Marketing authorization holders are obliged to provide their Package Leaflets in an accessible format

The all-clear can be given, because samples of the active substance noscapine from manufacturer and affected pharmacies have been examined in the meantime.

The Austrian Federal Office for Safety in Health Care has been informed by the European Commission about an update regarding the Novel Corona Virus (2019-nCoV).

Currently, in the area of open communications, an incorrect display of the letter symbol may occur during ongoing procedures.

Due to recent incidents with extemporaneously compounded products prepared noscapine cough syrup, it is recommended not to use extemporaneously compounded products noscapine cough syrup or suppositories from now on.

Recall due to suspension of the marketing authorization

Only available in German

Only available in German